The relevance of mouse models to understanding the development and progression of human breast cancer

Journal of Mammary Gland Biology and Neoplasia

Volumn 13, Issue 3, 2008, Pages 279-288

  Allred, D Craig ^a   Medina, Daniel ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Mouse model

Indexed keywords

CELECOXIB; ESTROGEN RECEPTOR ALPHA; MEDROXYPROGESTERONE ACETATE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOID DERIVATIVE; TAMOXIFEN;

BREAST CANCER; BREAST CARCINOGENESIS; BREAST HYPERPLASIA; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CHEMOPROPHYLAXIS; DRUG TARGETING; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; INTRADUCTAL CARCINOMA; METASTASIS; MOUSE; NONHUMAN; ONCOGENE; PRECANCER; REVIEW; TUMOR RECURRENCE;

ANIMALS; BREAST; BREAST NEOPLASMS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MEDICAL ONCOLOGY; MICE; MODELS, BIOLOGICAL; ONCOGENES;

EID: 50849102685     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10911-008-9093-5     Document Type: Review

References (91)

1. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res. 2008;14(2):370-8. doi: 10.1158/ 1078-0432.CCR-07-1127.
2. Wellings RR, Jensen HM. On the origin and progression of ductal carcinoma in the human breast. J Natl Cancer Inst. 1973;50:1111-8.
3. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst. 1975;55(2):231-73.
4. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90(18):1371-88. doi: 10.1093/jnci/90.18.1371.
5. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene STAR P-2 trial. JAMA. 2006;295(23):2727-41. doi: 10.1001/jama.295.23.joc60074.
6. Medina D. Mouse models for mammary cancer. In: Asch BB, Ip MM, editors. Methods in Mammary Gland Biology and Breast Cancer Research. New York: Kluwer Academic Press; 2000. p. 3-17.
7. Deome KB, Faulkin LJ Jr, Bern HA, Blair PB. Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free mammary fat pads of female C3H mice. Cancer Res. 1959;19(5):515-20.
8. Medina D. Premalignant and malignant mammary lesions induced by MMTV and chemical carcinogens. J Mammary Gland Biol Neoplasia. 2008. doi: 10.1007/ s10911-008-9086-4.
9. von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR. Ras activation in human breast cancer. Breast Cancer Res Treat. 2000;62(1):51-62. doi: 10.1023/A:1006491619920.
10. Borowsky A. Special considerations in mouse models of breast cancer. Breast Dis. 2007;28:29-38.
11. Shen Q, Brown PH. Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. J Mammary Gland Biol Neoplasia. 2003;8(1):45-73. doi: 10.1023/ A:1025783221557.
12. Boxer RB, Jang JW, Sintasath L, Chodosh LA. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell. 2004;6(6):577-86. doi: 10.1016/ j.ccr.2004.10.013.
13. Li W, Xiao C, Vonderhaar BK, Deng CX. A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation. Oncogene. 2007;26(51):7204-12. doi: 10.1038/sj.onc.1210527.
14. Lin SC, Lee KF, Nikitin AY, Hilsenbeck SG, Cardiff RD, Li A, et al. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res. 2004;64(10):3525-32. doi: 10.1158/0008-5472.CAN-03-3524.
15. Jang JW, Boxer RB, Chodosh LA. Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis. Mol Cell Biol. 2006;26(21):8109-21. doi: 10.1128/MCB.00404-06.
16. Du Z, Li Y. RCAS-TVA in the mammary gland: An in vivo oncogene screen and a high fidelity model for breast transformation? Cell Cycle. 2007;6(7):823-6.
17. Cardiff RD, Moghanaki D, Jensen RA. Genetically engineered mouse models of mammary intraepithelial neoplasia. J Mammary Gland Biol Neoplasia. 2000;5(4):421-37. doi: 10.1023/A:1009534129331.
18. Aidells BD, Daniel CW. Hormone-dependent mammary tumors in strain GR-A mice. I. Alternation between ductal and tumorous phases of growth during serial transplantation. J Natl Cancer Inst. 1974;52(6):1855-63.
19. Aidells BD, Daniel CW. Hormone-dependent mammary tumors in strain GR/A mice. IV. Origin and progression. J Natl Cancer Inst. 1978;60(6):1345-50.
20. Kordon EC, Molinolo AA, Pasqualini CD, Charreau EH, Pazos P, Dran G, et al. Progesterone induction of mammary carcinomas in BALB/c female mice. Correlation between progestin dependence and morphology. Breast Cancer Res Treat. 1993;28(1):29-39. doi: 10.1007/BF00666353.
21. Pazos P, Lanari C, Elizalde P, Montecchia F, Charreau EH, Molinolo AA. Promoter effect of medroxyprogesterone acetate (MPA) in N-methyl-N-nitrosourea (MNU) induced mammary tumors in BALB/c mice. Carcinogenesis. 1998;19(3):529-31. doi: 10.1093/carcin/19.3.529.
22. Efeyan A, Fabris V, Merani S, Lanari C, Molinolo AA. Establishment of two hormone-responsive mouse mammary carcinoma cell lines derived from a metastatic mammary tumor. Breast Cancer Res Treat. 2004;83(3):233-44. doi: 10.1023/B:BREA.0000014044.02728.ac.
23. Jerry DJ, Kittrell FS, Kuperwasser C, Laucirica R, Dickinson ES, Bonilla PJ, et al. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene. 2000;19(8):1052-8. doi: 10.1038/sj.onc.1203270.
24. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004;119(6):861-72. doi: 10.1016/j.cell.2004.11.006.
25. Medina D, Kittrell FS, Hill J, Shepard A, Thordarson G, Brown P. Tamoxifen inhibition of estrogen receptor-alpha-negative mouse mammary tumorigenesis. Cancer Res. 2005;65(8):3493-6.
26. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science. 2006;314(5804):1467-70. doi: 10.1126/ science.1130471.
27. Hu Y, Sun H, Drake J, Kittrell F, Abba MC, Deng L, et al. From mice to humans: Identification of commonly deregulated genes in mammary cancer via comparative SAGE studies. Cancer Res. 2004;64(21):7748-55. doi: 10.1158/0008-5472.CAN-04-1827.
28. Frech MS, Halama ED, Tilli MT, Singh B, Gunther EJ, Chodosh LA, et al. Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res. 2005;65(3):681-5.
29. Jones LP, Tilli MT, Assefnia S, Torre K, Halama ED, Parrish A, et al. Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene. 2008;27(6):794-802. doi: 10.1038/sj.onc.1210674.
30. Tilli MT, Frech MS, Steed ME, Hruska KS, Johnson MD, Flaws JA, et al. Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. Am J Pathol. 2003;163(5):1713-9.
31. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006;10(6):529-41. doi: 10.1016/ j.ccr.2006.10.009.
32. DePinho RA. The age of cancer. Nature. 2000;408(6809):248-54. doi: 10.1038/35041694.
33. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10(6):515-27. doi: 10.1016/ j.ccr.2006.10.008.
34. Goepfert TM, McCarthy M, Kittrell FS, Stephens C, Ullrich RL, Brinkley BR, et al. Progesterone facilitates chromosome instability (aneuploidy) in p53 null normal mammary epithelial cells. FASEB J. 2000;14(14):2221-9. doi: 10.1096/fj.00-0165com.
35. Pati D, Haddad BR, Haegele A, Thompson H, Kittrell FS, Shepard A, et al. Hormone-induced chromosomal instability in p53-null mammary epithelium. Cancer Res. 2004;64(16):5608-16. doi: 10.1158/0008-5472.CAN-03-0629.
36. Weaver Z, Montagna C, Xu X, Howard T, Gadina M, Brodie SG, et al. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene. 2002;21(33):5097-107. doi: 10.1038/sj.onc.1205636.
37. Li JJ, Weroha SJ, Lingle WL, Papa D, Salisbury JL, Li SA. Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci USA. 2004;101(52):18123-8. doi: 10.1073/pnas.0408273101.
38. Namba R, Maglione JE, Davis RR, Baron CA, Liu S, Carmack CE, et al. Heterogeneity of mammary lesions represent molecular differences. BMC Cancer. 2006;6:275. doi: 10.1186/1471-2407-6-275.
39. Milliken EL, Lozada KL, Johnson E, Landis MD, Seachrist DD, Whitten I, et al. Ovarian hyperstimulation induces centrosome amplification and aneuploid mammary tumors independently of alterations in p53 in a transgenic mouse model of breast cancer. Oncogene. 2008;27(12):1759-66. doi: 10.1038/sj.onc.1210815.
40. Suizu F, Ryo A, Wulf G, Lim J, Lu KP. Pin1 regulates centrosome duplication, and its overexpression induces centrosome amplification, chromosome instability, and oncogenesis. Mol Cell Biol. 2006;26(4):1463-79. doi: 10.1128/MCB.26.4.1463-1479.2006.
41. Chester N, Babbe H, Pinkas J, Manning C, Leder P. Mutation of the murine Bloom's syndrome gene produces global genome destabilization. Mol Cell Biol. 2006;26(17):6713-26. doi: 10.1128/MCB.00296-06.
42. Medina D, Kittrell FS, Shepard A, Stephens LC, Jiang C, Lu J, et al. Biological and genetic properties of the p53 null preneoplastic mammary epithelium. FASEB J. 2002;16(8):881-3.
43. Li Y, Zhang Y, Hill J, Kim HT, Shen Q, Bissonnette RP, et al. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer. 2008;98(8):1380-8. doi: 10.1038/ sj.bjc.6604320.
44. Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, et al. Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res. 2001;61(22):8298-305.
45. Schulze-Garg C, Lohler J, Gocht A, Deppert W. A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland. Oncogene. 2000;19(8):1028-37. doi: 10.1038/sj.onc.1203281.
46. Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R, et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene. 2007;26(11):1636-44. doi: 10.1038/sj.onc.1209955.
47. D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med. 2001;7(2):235-9. doi: 10.1038/84691.
48. Debies MT, Gestl SA, Mathers JL, Mikse OR, Leonard TL, Moody SE, et al. Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss. J Clin Invest. 2008;118(1):51-63. doi: 10.1172/JCI33320.
49. Gunther EJ, Moody SE, Belka GK, Hahn KT, Innocent N, Dugan KD, et al. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. 2003;17(4):488-501. doi: 10.1101/gad.1051603.
50. Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, Dugan KD, et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell. 2002;2(6):451-61. doi: 10.1016/S1535-6108(02)00212-X.
51. Damonte P, Gregg JP, Borowsky AD, Keister BA, Cardiff RD. EMT tumorigenesis in the mouse mammary gland. Lab Invest. 2007;87(12):1218-26. doi: 10.1038/labinvest.3700683.
52. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442-54. doi: 10.1038/nrc822.
53. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131-42. doi: 10.1038/nrm1835.
54. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell. 2005;8(3):197-209. doi: 10.1016/ j.ccr.2005.07.009.
55. Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, Sahai E, et al. Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res. 2004;64(23):8585-94. doi: 10.1158/0008-5472.CAN-04-1136.
56. Wang W, Wyckoff JB, Frohlich VC, Oleynikov Y, Huttelmaier S, Zavadil J, et al. Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res. 2002;62(21):6278-88.
57. Wang W, Wyckoff JB, Goswami S, Wang Y, Sidani M, Segall JE, et al. Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors. Cancer Res. 2007;67(8):3505-11. doi: 10.1158/0008-5472.CAN-06-3714.
58. Menard S, Aiello P, Tagliabue E, Rumio C, Lollini PL, Colnaghi MI, et al. Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. Cancer Res. 2000;60(2):273-5.
59. Namba R, Young LJ, Maglione JE, McGoldrick ET, Liu S, Wurz GT, et al. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res. 2005;7(6):R881-889. doi: 10.1186/bcr1317.
60. Yoshidome K, Shibata MA, Couldrey C, Korach KS, Green JE. Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: Paradoxical loss of estrogen receptoralpha expression during tumor progression. Cancer Res. 2000;60(24):6901-10.
61. Li Y, Zhang Y, Hill J, Shen Q, Kim HT, Xu X, et al. The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res. 2007;13(20):6224-31. doi: 10.1158/1078-0432.CCR-06-2681.
62. Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, et al. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 2002;11(5):467-74.
63. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res. 2004;2(11):632-42.
64. Yoshinaka R, Shibata MA, Morimoto J, Tanigawa N, Otsuki Y. COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer. Anticancer Res. 2006;26(6B):4245-54.
65. Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, et al. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003;95(24):1825-33.
66. Piechocki MP, Dibbley SK, Lonardo F, Yoo GH. Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu. Int J Cancer. 2008;122(8):1722-9. doi: 10.1002/ijc.23231.
67. Medina D, Lane HW. Stage specificity of selenium-mediated inhibition of mouse mammary tumorigenesis. Biol Trace Elem Res. 1983;5:297-306.
68. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, et al. FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin Cancer Res. 2007;13(15 Pt 1):4415-21. doi: 10.1158/ 1078-0432.CCR-07-0122.
69. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.
70. Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res. 2006;8(5):R61. doi: 10.1186/bcr1613.
71. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52. doi: 10.1038/35021093.
72. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869-74. doi: 10.1073/pnas.191367098.
73. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418-23. doi: 10.1073/pnas.0932692100.
74. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009. doi: 10.1056/NEJMoa021967.
75. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8(5):R76. doi: 10.1186/gb-2007-8-5-r76.
76. Deeb KK, Michalowska AM, Yoon CY, Krummey SM, Hoenerhoff MJ, Kavanaugh C, et al. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res. 2007;67(17):8065-80. doi: 10.1158/ 0008-5472.CAN-07-1515.
77. Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell. 2006;10(5):437-49. doi: 10.1016/j.ccr.2006.09.013.
78. Kim HJ, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X, et al. Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol. 2007;27(8):3165-75. doi: 10.1128/MCB.01315-06.
79. Dearth RK, Cui X, Kim HJ, Kuiatse I, Lawrence NA, Zhang X, et al. Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol. 2006;26(24):9302-14. doi: 10.1128/MCB.00260-06.
80. Morris VL, Koop S, MacDonald IC, Schmidt EE, Grattan M, Percy D, et al. Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth. Clin Exp Metastasis. 1994;12(6):357-67. doi: 10.1007/BF01755879.
81. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 1999;17(2):163-70. doi: 10.1023/A:1006689719505.
82. Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Res. 2001;61(18):6945-51.
83. Li Z, Schem C, Shi YH, Medina D, Zhang M. Increased COX2 expression enhances tumor-induced osteoclastic lesions in breast cancer bone metastasis. Clin Exp Metastasis 2007;25(4):389-400.
84. Bissell MJ, Kenny PA, Radisky DC. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: The role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol. 2005;70:343-56. doi: 10.1101/ sqb.2005.70.013.
85. Nelson CM, Inman JL, Bissell MJ. Three-dimensional lithographically defined organotypic tissue arrays for quantitative analysis of morphogenesis and neoplastic progression. Nat Protocols. 2008;3(4):674-8. doi: 10.1038/nprot.2008.35.
86. Barcellos-Hoff MH, Ravani SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 2000;60(5):1254-60.
87. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA. 2004;101(14):4966-71. doi: 10.1073/ pnas.0401064101.
88. Lin EY, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer. 2004;90(11):2053-8. doi: 10.1038/sj.bjc.6601705.
89. Condeelis J, Pollard JW. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124(2):263-6. doi: 10.1016/j.cell.2006.01.007.
90. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007;67(11):5064-6. doi: 10.1158/ 0008-5472.CAN-07-0912.
91. Hawsawi NM, Ghebeh H, Hendrayani SF, Tulbah A, Al-Eid M, Al-Tweigeri T, et al. Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. Cancer Res. 2008;68(8):2717-25. doi: 10.1158/0008-5472.CAN-08-0192.